ReviewFrontiers in oncology2023
An overview of extrahepatic cholangiocarcinoma: from here to where?
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- Renal Metastasis from Extrahepatic Cholangiocarcinoma Mimicking Renal Infarction: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Early-onset extrahepatic cholangiocarcinoma in a young adult with a resected congenital biliary cyst: a rare case report.Annals of medicine and surgery (2012) · 2026Article
- Survival benefit of surgical resection in elderly patients with extrahepatic cholangiocarcinoma: a propensity score-matched analysis.Langenbeck's archives of surgery · 2026Article
- Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies.Current pharmaceutical design · 2026Review
- Diagnosis of Perihilar Osteoclast Giant Cell Carcinoma in an Elderly Patient: A Report of Diagnostic Challenges Over Several Attempts.ACG case reports journal · 2025Article
- Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients.Journal of cancer research and clinical oncology · 2025Article
- Prognosis and Chemotherapeutic Efficacy in Extrahepatic Cholangiocarcinoma With Lung Metastases.Cancer reports (Hoboken, N.J.) · 2025Article
- Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.The oncologist · 2025Article
- Poorly Cohesive Carcinoma of Common Bile Duct: A Rare Histological Type of Cholangiocarcinoma.Clinical medicine insights. Case reports · 2025Article
- HTRecNet: a deep learning study for efficient and accurate diagnosis of hepatocellular carcinoma and cholangiocarcinoma.Frontiers in cell and developmental biology · 2025Article
- Efficacy and safety of biliary stenting combined withFrontiers in surgery · 2025Article
- HSPB8-BAG3 chaperone complex modulates cell invasion in intrahepatic cholangiocarcinoma by regulating CASA-mediated Filamin A degradation.Cancer biology & therapy · 2024Article
- Review
- Article
- Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.Current treatment options in oncology · 2024Review
- Prognostic model for oversurvival and tumor-specific survival prediction in patients with advanced extrahepatic cholangiocarcinoma: a population-based analysis.BMC gastroenterology · 2023Article
- Brucine suppresses proliferation and promotes apoptosis of human cholangiacarcinoma cells via the inhibition of COX2 expression.Journal of Cancer · 2023Article
- Forty-five-year trends in intra- and extrahepatic cholangiocarcinoma: sex- and race-based insights.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrahepatic cholangiocarcinoma (eCCA) contains perihilar cholangiocarcinoma and distal cholangiocarcinoma both of which can arise at any point of the biliary tree and originate from disparate anatomical sites. Generally, the incidence of eCCA is increasing globally. Though surgical resection is the principal treatment of choice for the early stages of eCCA, optimal survival remains restricted by the high risk of recurrence when most patients are present with unresectable disease or distant metastasis. Furthermore, both intra- and intertumoral heterogeneity make it laborious to determine molecularly targeted therapies. In this review, we mainly focused on current findings in the field of eCCA, mostly including epidemiology, genomic abnormalities, molecular pathogenesis, tumor microenvironment, and other details while a summary of the biological mechanisms driving eCCA may shed light on intricate tumorigenesis and feasible treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.